bcbs fep glp-1 coverage 2025 Insurance Tips for Obesity Medications IBX members face GLP-1 drug

Sources Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist (PMC) Application of nutrition interventions with GLP-1 based therapies: a narrative review (PMC) Endocrine Society: Consuming more protein may protect patients taking anti-obesity drug from muscle loss (ENDO 2025) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists (PMC) MedlinePlus: Fiber MedlinePlus: High-fiber foods Mayo Clinic Health System: Assessing protein needs Mayo Clinic: High-protein snacks Therapeutic Benefits and Dietary Restrictions of Fiber Intake (PMC)

The current study Study author Yuya Koide and his colleagues wanted to explore how individuals with type 2 diabetes respond to GLP-1RAs therapy (Koide et al., 2025)

Well-studied, well-tolerated for most clients, and an excellent starting point for those new to GLP-1 therapy

P = 0.24

Serious adverse effects requiring clinical vigilance include: Lactic acidosis : A rare but potentially fatal complication of metformin, particularly in patients with renal impairment (eGFR 10%), symptomatic hyperglycemia, diagnostic uncertainty, or recurrent hypoglycemia